Last reviewed · How we verify
Durvalumab +Tremelimumab
Durvalumab and tremelimumab together block PD-L1 and CTLA-4 checkpoints to unleash dual immune activation against cancer cells.
Durvalumab and tremelimumab together block PD-L1 and CTLA-4 checkpoints to unleash dual immune activation against cancer cells. Used for Unresectable hepatocellular carcinoma, Metastatic or unresectable non-small cell lung cancer, Biliary tract cancer.
At a glance
| Generic name | Durvalumab +Tremelimumab |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Dual checkpoint inhibitor combination (PD-L1 inhibitor + CTLA-4 inhibitor) |
| Target | PD-L1 and CTLA-4 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Durvalumab is a PD-L1 inhibitor that blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, restoring anti-tumor immunity. Tremelimumab is a CTLA-4 inhibitor that removes another inhibitory signal on T cells. Combined, they provide complementary checkpoint blockade to enhance T-cell proliferation, activation, and tumor infiltration.
Approved indications
- Unresectable hepatocellular carcinoma
- Metastatic or unresectable non-small cell lung cancer
- Biliary tract cancer
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Immune-mediated hepatitis
- Immune-mediated colitis
- Rash
- Decreased appetite
Key clinical trials
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- IIT2025-03-YANG-LIFT-HCC (PHASE2)
- Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens (PHASE1)
- TheraSphere With Durvalumab and Tremelimumab for HCC (PHASE2)
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (PHASE2)
- Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer (PHASE2)
- Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma (PHASE2)
- Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Durvalumab +Tremelimumab CI brief — competitive landscape report
- Durvalumab +Tremelimumab updates RSS · CI watch RSS
- AstraZeneca portfolio CI